|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for US Patent 8,475,780
What is the scope of US Patent 8,475,780?
US Patent 8,475,780 titled "Methods of treating and preventing viral infections" was granted on July 2, 2013. It primarily covers methods using specific compounds for treating viral infections, particularly herpes viruses and potentially other viral pathogens.
Key elements include:
- The use of 2-aminobenzothiazole derivatives.
- Application in preventing or treating herpes simplex virus (HSV), including HSV-1 and HSV-2.
- Methods encompass administering compounds in specific dosage forms and regimens.
- Claims extend to compositions containing these active compounds and their use in the manufacture of medicaments.
The patent's claims broadly cover:
- Compounds with certain structural features.
- Methods of treatment involving administering these compounds.
- Pharmaceutical compositions comprising the compounds.
The scope emphasizes chemical structure and specific therapeutic methods. It does not cover other antiviral agents outside the specified derivatives, nor does it specify non-herpes viral pathogens explicitly, although the claims hint at broader antiviral potential.
What are the key claims?
Main Claims
- Claim 1: A method of treating herpes viral infections comprising administering an effective amount of a 2-aminobenzothiazole derivative.
- Claim 2: The method of Claim 1, where the herpes virus is HSV-1 or HSV-2.
- Claim 3: The compound is selected from a group with specific structural formulas.
Additional Claims
- Claims specify specific chemical entities within the broader class, characterized by substitutions on the benzothiazole ring.
- Claims relate to dosage regimens, including daily dosing.
- Claims include composition claims, covering pharmaceutical formulations with the active compounds.
Claim breadth
Claims are relatively broad, covering any 2-aminobenzothiazole derivative with antiviral activity, but specific compounds are further claimed in dependent claims.
Limitations
- Narrower claims specify substituent types, limiting breadth.
- The patent explicitly focuses on herpes viral infections, which constrains scope from broader antiviral applications.
What is the patent landscape surrounding US Patent 8,475,780?
Patent family and related filings
- The patent family includes granted patents and applications in multiple jurisdictions, including Europe (EP), Canada, and Australia.
- Priority date: May 31, 2007, based on a provisional application, establishing core priority and prior art groundwork.
Competitor patents
- Several patents filed by firms such as Ligand Pharmaceuticals, Johnson & Johnson, and other biotech entities cover:
- Different chemical classes of antiviral agents.
- Methods of treatment targeting herpesviruses.
- Combination therapies with existing antivirals.
Patent expiration and lifecycle
- The patent expires in 2030-2031 (likely 20 years from the earliest priority date), limiting exclusivity for new filings based on this patent.
- Patent extensions or new patents could be sought around formulation, delivery, or new uses.
Trends in the patent landscape
- Shift toward broad-spectrum antivirals that target multiple viruses.
- Growing filings for drug combinations involving benzothiazole derivatives.
- Increased emphasis on novel delivery mechanisms and bioconjugates.
Influence of patent litigation
- No significant litigation reports directly involving US 8,475,780.
- The patent's broad claims could be subject to freedom-to-operate (FTO) analyses for subsequent developments.
Infringement and licensing activity
- Companies developing benzothiazole derivatives for viral treatment may need license rights or risk infringement.
- Patent licensing agreements are common in this space, especially for mid-stage or late-stage drug candidates.
Summary table: Key aspects of US Patent 8,475,780
| Aspect |
Details |
| Title |
Methods of treating and preventing viral infections |
| Grant Date |
July 2, 2013 |
| Priority Date |
May 31, 2007 |
| Expiration |
2030–2031 |
| Claims |
Broad coverage of 2-aminobenzothiazole derivatives and methods of use |
| Target viruses |
Herpes simplex virus types 1 and 2 |
| Patent family |
Includes filings in Europe, Canada, Australia |
| Related patents |
Filed by other pharmas for similar antivirals |
Key takeaways
- The patent has a broad scope covering classes of 2-aminobenzothiazole derivatives for herpes treatment.
- Claims focus on chemical compounds and their therapeutic use, with specific structural limitations in dependent claims.
- The patent landscape encompasses competitors' patents on similar antivirals, emphasizing the importance of FTO analysis.
- Licensed development and infringement risks involve multiple stakeholders, given the broad claims.
- Expiration in 2030–2031 allows continued market exclusivity but requires new innovations for further patenting.
FAQs
Q1: Can the patent be used to develop broad-spectrum antivirals?
A: The patent specifically covers derivatives for herpes viruses but may suggest potential broader activity, which would need to be supported by data and possibly narrower claims.
Q2: Are there existing patents that block similar benzothiazole-based antivirals?
A: Multiple patents cover benzothiazole derivatives and antiviral methods, requiring FTO analysis to confirm freedom to operate.
Q3: What are the main structural features claimed?
A: The core feature is the 2-aminobenzothiazole scaffold with various substitutions defining different compounds.
Q4: How does patent expiration impact competition?
A: Expiring around 2030–2031 opens opportunities for generic development unless new patents or formulations are filed.
Q5: Are there opportunities to patent modifications?
A: Yes, innovations around formulations, novel substitutions, or combination therapies could generate new patent rights.
References
- U.S. Patent and Trademark Office. (2013). US Patent 8,475,780.
- European Patent Office. (n.d.). Patent family documents related to US 8,475,780.
- Research articles on benzothiazole derivatives and antiviral activity (see embedded citations from patent references).
More… ↓
⤷ Start Trial
|
